Announcement • Jun 22
Kyverna Therapeutics, Inc. Announces Appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, Effective June 22, 2026 Kyverna Therapeutics, Inc. announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Mr. Srivastava brings extensive experience spanning legal, corporate strategy, compliance, and risk management, which will further support Kyverna as it advances miv-cel (mivocabtagene autoleucel, KYV-101) towards a potential first approval in stiff person syndrome and transitions to a commercial-stage organization. Mr. Srivastava joined Kyverna from BPGbio, where he served as General Counsel and provided legal and strategic counsel across research and development, commercialization planning, and business operations. Prior to BPGbio, he served as Global Compliance Officer at Spectrum Pharmaceuticals, where he also advised the Board of Directors and its committees on corporate governance, risk management, and public company disclosure matters, and counseled on commercial transactions and strategic initiatives. Earlier, he served as Director of Compliance and Investigations at Avanir Pharmaceuticals. As a former federal prosecutor with the United States Department of Justice, Mr. Srivastava led law enforcement teams in the investigation and prosecution of healthcare fraud and anti-kickback matters. Earlier in his career, Mr. Srivastava was a private practice litigator at Cooley LLP, where he provided legal counsel to pharmaceutical, biotechnology, and medical device companies. He began his career as an officer with the Navy’s Judge Advocate General Corps, where he served for six years as a trial defense lawyer and later as Appellate Government Counsel, ultimately achieving the rank of Lieutenant Commander. He holds a Juris Doctor from Pepperdine University School of Law and a Bachelor of Science degree from Columbia University. Announcement • May 19
Kyverna Therapeutics, Inc. Announces Chief Financial Officer Changes Kyverna Therapeutics, Inc. announced the appointment of Greg Martini as Chief Financial Officer (CFO), effective May 18, 2026. Mr. Martini succeeds Dr. Marc Grasso who will be consulting for the Company to ensure a seamless transition. With this appointment, Mr. Martini will lead Kyverna’s financial strategy and operations, including corporate finance, capital allocation, and investor relations, as the Company advances miv-cel (mivocabtagene autoleucel, KYV-101) toward a potential first approval in stiff person syndrome and prepares for its transition to a commercial-stage organization. Mr. Martini joins Kyverna from Ironwood Pharmaceuticals, a biotechnology company commercializing therapies for patients with gastrointestinal and rare diseases, where he most recently served as Senior Vice President and CFO. In this position, he led capital allocation, treasury, and investor relations, supporting the commercial expansion of LINZESS (linaclotide) and positive EBITDA and cash flow growth while driving significant operational savings. Previously, as Vice President of Strategic Finance and Investor Relations at Ironwood, he served as a key company spokesperson to the investment community and redefined Ironwood's equity story following its $1.1 billion acquisition of VectivBio. Earlier in his career, Mr. Martini held finance and corporate development roles at Thermo Fisher Scientific, completing several acquisitions and divestitures, and also held positions at Ernst & Young and Raytheon Technologies. Mr. Martini holds a B.S. in Finance, summa cum laude, from Bentley University. Announcement • May 05
Kyverna Therapeutics, Inc. Appoints Nadia Dac as Chief Commercial Officer, Effective May 4, 2026 Kyverna Therapeutics, Inc. announced the appointment of veteran commercial leader Nadia Dac as Chief Commercial Officer, effective May 4, 2026. With more than 30 years of US and global commercial leadership in the biopharmaceutical industry, Ms. Dac has deep experience successfully executing new product launches and building high-performing commercial organizations, including those making the transition to commercial-stage for the first time. At Kyverna, she will lead commercial strategy and execution for miv-cel (mivocabtagene autoleucel, KYV-101), which is poised to be the first treatment approved for patients with stiff person syndrome, followed by anticipated expansion into other neuroimmunology diseases. Ms. Dac most recently served as Chief Commercial Officer at Omeros Corporation, where she built and led the commercial organization for rare disease programs in hematologic and immune-mediated conditions, including the launch of Yartemlea®, the first FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. Prior to Omeros, she served as CCO at Alder Biopharmaceuticals, Inc., where she led the commercial launch of Vyepti® in migraine prevention, prior to the company’s acquisition by Lundbeck. Previously, Ms. Dac served as Vice President of Global Specialty Commercial Development at AbbVie, where she led portfolio strategy and optimization across rare disease and neuroscience, supporting the advancement and lifecycle management of multiple specialty assets within complex, highly competitive markets. Prior to AbbVie, she was Vice President of Marketing at Auxilium Pharmaceuticals, Inc., where she oversaw the launch and commercialization of a portfolio of men’s health products ahead of the company’s acquisition by Endo International plc. Earlier in her career, Ms. Dac held roles of increasing responsibility at Novartis, building the commercial infrastructure that effectively launched Gilenya® and Extavia® in multiple sclerosis; held marketing and leadership roles at Biogen, with responsibility for multiple sclerosis brands, including Tysabri® and Avonex®; and supported the Alzheimer’s therapy, Aricept® at Pfizer. She also spent nearly a decade in neuroscience marketing and sales roles at Johnson & Johnson and Eli Lilly and Company. Ms. Dac holds a B.S. in Marketing from Rutgers University. 
